Last reviewed · How we verify
Acute decompensated heart failure in patients receiving digoxin — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Milrinone Lactate | Milrinone Lactate | Pfizer Inc. | Inotropic agent; Phosphodiesterase-3 inhibitor; Vasodilator | Phosphodiesterase-3 (PDE-3) enzyme |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer Inc. · 1 drug in Acute decompensated heart failure in patients receiving digoxin
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Acute decompensated heart failure in patients receiving digoxin:
- Acute decompensated heart failure in patients receiving digoxin treatment updates — RSS
- Acute decompensated heart failure in patients receiving digoxin treatment updates — Atom
- Acute decompensated heart failure in patients receiving digoxin treatment updates — JSON
Cite this brief
Drug Landscape (2026). Acute decompensated heart failure in patients receiving digoxin — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/acute-decompensated-heart-failure-in-patients-receiving-digoxin. Accessed 2026-06-10.
Related
- Acute decompensated heart failure in patients receiving digoxin full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing